JP7071330B2 - 炭酸水素ナトリウムのｉｎ ｓｉｔｕ変換で促進されたアミン薬物の経皮送達 - Google Patents

炭酸水素ナトリウムのｉｎ ｓｉｔｕ変換で促進されたアミン薬物の経皮送達 Download PDF

Info

Publication number
JP7071330B2
JP7071330B2 JP2019504000A JP2019504000A JP7071330B2 JP 7071330 B2 JP7071330 B2 JP 7071330B2 JP 2019504000 A JP2019504000 A JP 2019504000A JP 2019504000 A JP2019504000 A JP 2019504000A JP 7071330 B2 JP7071330 B2 JP 7071330B2
Authority
JP
Japan
Prior art keywords
weight
pressure
composition
composition according
drug reservoir
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019504000A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019525932A5 (enExample
JP2019525932A (ja
Inventor
ウン ス リ，
パーミンダー シン，
アパラ サギ，
アミット ケー． ジェイン，
Original Assignee
コリウム， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コリウム， インコーポレイテッド filed Critical コリウム， インコーポレイテッド
Publication of JP2019525932A publication Critical patent/JP2019525932A/ja
Publication of JP2019525932A5 publication Critical patent/JP2019525932A5/ja
Priority to JP2022076575A priority Critical patent/JP2022093707A/ja
Application granted granted Critical
Publication of JP7071330B2 publication Critical patent/JP7071330B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7092—Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
    • C08K5/00—Use of organic ingredients
    • C08K5/0008—Organic ingredients according to more than one of the "one dot" groups of C08K5/01 - C08K5/59
    • C08K5/0016—Plasticisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Polymers & Plastics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019504000A 2016-07-27 2017-07-26 炭酸水素ナトリウムのｉｎ ｓｉｔｕ変換で促進されたアミン薬物の経皮送達 Active JP7071330B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022076575A JP2022093707A (ja) 2016-07-27 2022-05-06 炭酸水素ナトリウムのｉｎ ｓｉｔｕ変換で促進されたアミン薬物の経皮送達

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US201662367542P 2016-07-27 2016-07-27
US201662367502P 2016-07-27 2016-07-27
US62/367,542 2016-07-27
US62/367,502 2016-07-27
US201662423133P 2016-11-16 2016-11-16
US62/423,133 2016-11-16
US201762444763P 2017-01-10 2017-01-10
US201762444745P 2017-01-10 2017-01-10
US62/444,763 2017-01-10
US62/444,745 2017-01-10
US201762457794P 2017-02-10 2017-02-10
US62/457,794 2017-02-10
US201762504391P 2017-05-10 2017-05-10
US201762504408P 2017-05-10 2017-05-10
US62/504,408 2017-05-10
US62/504,391 2017-05-10
PCT/US2017/044049 WO2018022816A1 (en) 2016-07-27 2017-07-26 Sodium bicarbonate in situ conversion driven transdermal delivery of amine drug

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022076575A Division JP2022093707A (ja) 2016-07-27 2022-05-06 炭酸水素ナトリウムのｉｎ ｓｉｔｕ変換で促進されたアミン薬物の経皮送達

Publications (3)

Publication Number Publication Date
JP2019525932A JP2019525932A (ja) 2019-09-12
JP2019525932A5 JP2019525932A5 (enExample) 2020-08-27
JP7071330B2 true JP7071330B2 (ja) 2022-05-18

Family

ID=59523314

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2019504000A Active JP7071330B2 (ja) 2016-07-27 2017-07-26 炭酸水素ナトリウムのｉｎ ｓｉｔｕ変換で促進されたアミン薬物の経皮送達
JP2019504001A Active JP7251033B2 (ja) 2016-07-27 2017-07-26 ドネペジル経皮送達システム
JP2019503974A Active JP7153010B2 (ja) 2016-07-27 2017-07-26 塩薬物のｉｎ ｓｉｔｕでの塩から中性の薬物変換による、低溶解度または不安定非イオン化中性薬物の経皮配合物および送達方法
JP2022076575A Pending JP2022093707A (ja) 2016-07-27 2022-05-06 炭酸水素ナトリウムのｉｎ ｓｉｔｕ変換で促進されたアミン薬物の経皮送達
JP2022106083A Pending JP2022121629A (ja) 2016-07-27 2022-06-30 ドネペジル経皮送達システム
JP2022124683A Pending JP2022140751A (ja) 2016-07-27 2022-08-04 塩薬物のｉｎ ｓｉｔｕでの塩から中性の薬物変換による、低溶解度または不安定非イオン化中性薬物の経皮配合物および送達方法

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2019504001A Active JP7251033B2 (ja) 2016-07-27 2017-07-26 ドネペジル経皮送達システム
JP2019503974A Active JP7153010B2 (ja) 2016-07-27 2017-07-26 塩薬物のｉｎ ｓｉｔｕでの塩から中性の薬物変換による、低溶解度または不安定非イオン化中性薬物の経皮配合物および送達方法
JP2022076575A Pending JP2022093707A (ja) 2016-07-27 2022-05-06 炭酸水素ナトリウムのｉｎ ｓｉｔｕ変換で促進されたアミン薬物の経皮送達
JP2022106083A Pending JP2022121629A (ja) 2016-07-27 2022-06-30 ドネペジル経皮送達システム
JP2022124683A Pending JP2022140751A (ja) 2016-07-27 2022-08-04 塩薬物のｉｎ ｓｉｔｕでの塩から中性の薬物変換による、低溶解度または不安定非イオン化中性薬物の経皮配合物および送達方法

Country Status (10)

Country Link
US (13) US20180028463A1 (enExample)
EP (3) EP3490541B1 (enExample)
JP (6) JP7071330B2 (enExample)
KR (9) KR102406482B1 (enExample)
CN (5) CN109789105B (enExample)
AU (7) AU2017302307A1 (enExample)
CA (3) CA3281579A1 (enExample)
MX (2) MX394249B (enExample)
SG (1) SG11201900692WA (enExample)
WO (3) WO2018022816A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170110083A (ko) 2014-12-23 2017-10-10 인털렉츄얼 프라퍼티 어쏘시에이츠, 엘엘씨 경피 투여를 위한 방법 및 제형
WO2017083920A1 (en) * 2015-11-18 2017-05-26 Commonwealth Scientific And Industrial Research Organisation Rice grain with thickened aleurone
US10835499B2 (en) 2015-12-30 2020-11-17 Corium, Inc. Systems and methods for long term transdermal administration
CN109922796B (zh) 2016-06-23 2023-04-07 考里安有限责任公司 具有亲水和疏水域的粘合剂基质和治疗剂
EP3490544A1 (en) 2016-07-27 2019-06-05 Corium International, Inc. Memantine transdermal delivery systems
JP7071330B2 (ja) 2016-07-27 2022-05-18 コリウム， インコーポレイテッド 炭酸水素ナトリウムのｉｎ ｓｉｔｕ変換で促進されたアミン薬物の経皮送達
EP3658127A1 (en) * 2017-07-26 2020-06-03 Corium, Inc. Transdermal delivery system with a microporous membrane having solvent-filled pores
EP4324460A3 (en) * 2017-09-15 2024-04-24 Dyve Biosciences, Inc. Sodium bicarbonate for use in the treatment of gout and related disorders
WO2019126531A1 (en) 2017-12-20 2019-06-27 Corium, Inc. Transdermal adhesive composition comprising a volatile liquid therapeutic agent having low melting point
KR102710072B1 (ko) * 2018-08-31 2024-09-24 에스케이케미칼 주식회사 장기 투여용 리바스티그민 패취
KR102823139B1 (ko) * 2018-08-31 2025-06-19 에스케이케미칼 주식회사 장기 투여용 리바스티그민 패취
KR102115102B1 (ko) 2018-12-21 2020-05-26 동아에스티 주식회사 안정화된 도네페질 함유 경피 흡수제제
KR102372630B1 (ko) * 2019-05-15 2022-03-14 주식회사 대웅제약 고함량의 도네페질 또는 그의 염을 포함하는 경피흡수제제
US11101101B2 (en) * 2019-05-15 2021-08-24 Fei Company Laser-based phase plate image contrast manipulation
US20230233480A1 (en) * 2019-10-24 2023-07-27 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system for the transdermal administration of fingolimod
EP4066829A4 (en) * 2019-11-26 2023-12-27 Hisamitsu Pharmaceutical Co., Inc. METHOD FOR IMPROVING THE HOLDING POWER OF AN ADHESIVE LAYER IN A ROPINIROL-CONTAINING TRANSDERMAL PATCH AND ROPINIROL-CONTAINING TRANSDERMAL PATCH WITH IMPROVED HOLDING POWER
CN114829580A (zh) * 2019-12-18 2022-07-29 先锋国际良种公司 用于提高植物籽粒产量的组合物和方法
US20230123388A1 (en) * 2020-04-14 2023-04-20 Glanis Pharmaceuticals, Inc. Transdermal and/or topical delivery system comprising hydroxychloroquine and/or chloroquine
JP2022044038A (ja) * 2020-09-04 2022-03-16 株式会社大石膏盛堂 ドネペジル含有経皮吸収液剤およびその製造方法
CN112656778A (zh) * 2020-12-28 2021-04-16 广东红珊瑚药业有限公司 一种压敏胶基质以及一种贴剂
US12270039B2 (en) * 2021-05-14 2025-04-08 Board Of Trustees Of Southern Illinois University Compositions and methods to increase oleic acid content in soybeans
US12270040B2 (en) * 2021-05-27 2025-04-08 Board Of Trustees Of Southern Illinois University Soybean lines with low saturated fatty acid and high oleic acid contents
EP4362921A2 (en) * 2021-06-28 2024-05-08 Corium, LLC Corona discharge treated transdermal delivery system
CR20240001A (es) * 2021-07-08 2024-05-22 Monsanto Technology Llc Proteínas inhibidoras de insectos novedosas
MX2024008709A (es) * 2022-01-12 2024-07-22 Inari Agriculture Tech Inc Maiz de altura reducida.
WO2025103446A1 (zh) * 2023-11-16 2025-05-22 宜昌人福药业有限责任公司 含有多奈哌齐的透皮贴剂及其制备方法

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995028914A1 (en) 1994-04-21 1995-11-02 Hisamitsu Pharmaceutical Co., Inc. Percutaneously administrable base composition and percutaneously administrable drug composition prepared therefrom
JP2002275066A (ja) 2001-03-15 2002-09-25 Kyukyu Yakuhin Kogyo Kk 粘膜貼付剤
US20040022835A1 (en) 2002-01-17 2004-02-05 Samyang Corporation Transdermal composition of an antivomiting agent
WO2005115355A1 (ja) 2004-05-28 2005-12-08 Hisamitsu Pharmaceutical Co., Inc. 貼付製剤
JP2007302582A (ja) 2006-05-09 2007-11-22 Hisamitsu Pharmaceut Co Inc ドネペジル経皮吸収型製剤
JP2008530217A (ja) 2005-02-18 2008-08-07 マイラン・テクノロジーズ，インコーポレイテッド 制御送達システムを有する経皮システム
JP2009542657A (ja) 2006-06-29 2009-12-03 ジャズ ファーマシューティカルズ ゲルの形態でのロピニロール含有薬学的組成物、その使用
JP2010538064A (ja) 2007-09-04 2010-12-09 マイラン・テクノロジーズ，インコーポレイテッド 被覆剥離ライナを含む経皮薬物送達システム
JP2011518795A (ja) 2008-04-25 2011-06-30 アシノ アーゲー フェンタニルまたはその類似化合物を投与するための経皮治療システム
WO2011105486A1 (ja) 2010-02-24 2011-09-01 久光製薬株式会社 貼付剤
JP2012255044A (ja) 2006-12-01 2012-12-27 Nitto Denko Corp ドネペジル含有貼付製剤の経時的な変色を抑制する方法
JP2013075856A (ja) 2011-09-30 2013-04-25 Tokuyama Corp 貼付剤
JP2013528631A (ja) 2010-06-17 2013-07-11 エルテーエス ローマン テラピー−ジステーメ アーゲー メマンチンの経皮投与
JP2014514351A (ja) 2011-05-12 2014-06-19 シャンハイ テックウェル バイオファーマスーティカル カンパニー リミテッド ミカファンギンナトリウムの製造方法
WO2015072564A1 (ja) 2013-11-17 2015-05-21 株式会社メドレックス 経皮吸収型コロイド液剤

Family Cites Families (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3391142A (en) 1966-02-09 1968-07-02 Lilly Co Eli Adamantyl secondary amines
NL134681C (enExample) 1966-04-26
US3546141A (en) 1966-08-08 1970-12-08 Mc Donnell Douglas Corp Phosphorus-nitrogen polymers and process
NL7305644A (enExample) 1972-04-20 1973-10-23
DE2856393C2 (de) 1978-12-27 1983-04-28 Merz + Co GmbH & Co, 6000 Frankfurt Arzneimittel zur Behandlung von Morbus Parkinson
DE3572485D1 (en) 1984-12-22 1989-09-28 Thomae Gmbh Dr K Tetrahydro-benzothiazoles, their production and their use as intermediates or drugs
US4797284A (en) * 1986-03-12 1989-01-10 Merck & Co., Inc. Transdermal drug delivery system
US4880633A (en) 1986-03-12 1989-11-14 Merck & Co., Inc. Transdermal drug delivery system
DE3634016A1 (de) 1986-04-17 1987-10-29 Lohmann Gmbh & Co Kg Flaechenfoermiges therapeutisches system, verfahren zu seiner herstellung und seine verwendung
FI95572C (fi) 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
US4837027A (en) 1987-11-09 1989-06-06 Alza Corporation Transdermal drug delivery device
US4781924A (en) 1987-11-09 1988-11-01 Alza Corporation Transdermal drug delivery device
US4849224A (en) 1987-11-12 1989-07-18 Theratech Inc. Device for administering an active agent to the skin or mucosa
US5026556A (en) 1988-11-10 1991-06-25 Norwich Eaton Pharmaceuticals, Inc. Compositions for the transdermal delivery of pharmaceutical actives
CA2007181C (en) * 1989-01-06 1998-11-24 Angelo Mario Morella Sustained release pharmaceutical composition
DE10299048I2 (de) 1989-04-14 2006-07-13 Merz Pharma Gmbh & Co Kgaa Verwendung von Adamantan-Derivaten zur Pr{vention und Behandlung der cerebralen Isch{mie
DE3913734C2 (de) * 1989-04-26 1998-08-20 Roehm Gmbh Verwendung einer wäßrigen Hauthaftkleberlösung zur Herstellung einer mit Wasser leicht abwaschbaren Klebschicht
MY115126A (en) * 1990-04-27 2003-04-30 Seikisui Chemical Co Ltd Percutaneously absorbable eperisone or tolperisone preparation.
US5252588A (en) * 1990-04-27 1993-10-12 Sekisui Kagaku Kogyo Kabushiki Kaisha Percutaneously absorbable crosslinked polyvinylpyrrolidone eperisone or tolperisone preparation
IE62597B1 (en) 1990-07-23 1995-02-08 Alza Corp Oral osmotic device for delivering nicotine
US5614560A (en) 1991-04-04 1997-03-25 Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
US5123900A (en) 1991-08-16 1992-06-23 Bertek, Inc. Moisture permeable double disk
JPH06199659A (ja) 1992-10-28 1994-07-19 Hisamitsu Pharmaceut Co Inc 経皮治療用装置
DE4310012A1 (de) * 1993-03-27 1994-09-29 Roehm Gmbh Dermales therapeutisches System aus einer schmelzfähigen Poly(meth)acrylat-Mischung
US5424077A (en) 1993-07-13 1995-06-13 Church & Dwight Co., Inc. Co-micronized bicarbonate salt compositions
ATE194281T1 (de) 1994-09-14 2000-07-15 Minnesota Mining & Mfg Matrix für transdermale wirkstofffreisetzung
US5635203A (en) * 1994-09-29 1997-06-03 Alza Corporation Transdermal device having decreased delamination
CA2208132A1 (en) 1994-12-21 1996-06-27 Theratech, Inc. Transdermal delivery system with adhesive overlay and peel seal disc
WO1996040087A2 (en) 1995-06-07 1996-12-19 Cygnus, Inc. Pressure sensitive acrylate adhesive composition cross-linked with aluminum acetylacetonate and containing a drug having a reactive aromatic hydroxyl group
DE19531342B4 (de) 1995-08-25 2007-11-29 Merz Pharma Gmbh & Co. Kgaa Verwendung von Aminoadamantan-Verbindungen als Immunregulatoren
US6929801B2 (en) 1996-02-19 2005-08-16 Acrux Dds Pty Ltd Transdermal delivery of antiparkinson agents
US6512010B1 (en) 1996-07-15 2003-01-28 Alza Corporation Formulations for the administration of fluoxetine
US5958919A (en) 1996-09-20 1999-09-28 Washington University Treatment of presymptomatic alzheimer's disease to prevent neuronal degeneration
ES2191834T3 (es) 1996-10-24 2003-09-16 Alza Corp Agentes que facilitan la permeacion y destinados para composiciones, dispositivos y procedimientos de aporte transdermico de medicamentos.
CN1174031A (zh) * 1997-04-23 1998-02-25 谢先运 双氯芬酸钠透皮控释贴膏
US5866585A (en) 1997-05-22 1999-02-02 Synchroneuron, Llc Methods of treating tardive dyskinesia using NMDA receptor antagonists
US20040018241A1 (en) * 1997-09-26 2004-01-29 Noven Pharmaceuticals, Inc. Bioadhesive compositions and methods for topical administration of active agents
US6193993B1 (en) 1998-03-03 2001-02-27 Eisai Co., Ltd. Suppository containing an antidementia medicament
JP4205778B2 (ja) * 1998-04-17 2009-01-07 久光製薬株式会社 貼付製剤
DE19820999A1 (de) 1998-05-11 1999-11-18 Lohmann Therapie Syst Lts Laminat zum Aufbringen auf einen Akzeptor
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6562368B2 (en) * 1999-12-16 2003-05-13 Dermatrends, Inc. Transdermal administration of oxybutynin using hydroxide-releasing agents as permeation enhancers
US20020192243A1 (en) 1999-12-16 2002-12-19 Tsung-Min Hsu Transdermal and topical administration of drugs for the treatment of Alzheimer's disease using basic enhancers
US6455066B1 (en) 2000-03-10 2002-09-24 Epicept Corporation Intradermal-penetration agents for topical local anesthetic administration
US7276249B2 (en) 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
JP3962684B2 (ja) * 2000-11-06 2007-08-22 サムヤン コーポレイション 改善された水分吸収能および接着性を有する経皮投与剤
US20040028724A1 (en) * 2000-11-07 2004-02-12 Takaaki Terahara Pharmaceutical preparation of percutaneous absorption type
ATE438418T1 (de) 2001-05-01 2009-08-15 Av Topchiev Inst Petrochemical Hydrogel-zusammensetzungen
CA2457011C (en) 2001-08-20 2012-04-24 Maiken Nedergaard Treatment of glial tumors with glutamate antagonists
NZ531404A (en) * 2001-09-04 2006-03-31 Trommsdorff Gmbh & Co Plaster for the treatment of dysfunctions and disorders of nails, comprising sertaconazole
KR20050037405A (ko) * 2001-10-17 2005-04-21 히사미쯔 제약 주식회사 경피 흡수형 제제
ITMI20012827A1 (it) * 2001-12-28 2003-06-28 Fidia Farmaceutici Formulazioni adesive transdermiche di diclofenac sodico
CN100339070C (zh) 2002-10-24 2007-09-26 莫茨药物股份两合公司 包含1－氨基环己烷衍生物类和乙酰胆碱酯酶抑制剂类的药物组合物
CA2538856C (en) 2003-10-10 2010-06-29 Antares Pharma Ipl Ag Transdermal pharmaceutical formulation for minimizing skin residues
EP1682060A1 (en) * 2003-10-14 2006-07-26 Dermatrends, Inc. Enhancing transdermal administration of hydrophilic drugs
AU2004316119B2 (en) 2003-10-22 2008-04-24 Merz Pharma Gmbh & Co. Kgaa The use of 1-aminocyclohexane derivatives to modify deposition of fibrillogenic AB peptides in amyloidopathies
CA2543295A1 (en) 2003-10-23 2005-05-06 Trans1 Inc. Tools and tool kits for performing minimally invasive procedures on the spine
AU2004292966A1 (en) 2003-11-21 2005-06-09 Memory Pharmaceutical Corporation Compositions and methods of treatment using L-type calcium channel blockers and cholinesterase inhibitors
US7176185B2 (en) 2003-11-25 2007-02-13 Tsrl, Inc. Short peptide carrier system for cellular delivery of agent
KR20070030178A (ko) 2004-02-17 2007-03-15 트랜스오랄 파마슈티칼스, 인코포레이티드 구강 점막을 가로지르는 수면제 전달용 조성물 및 이의사용 방법
US7670838B2 (en) 2004-05-24 2010-03-02 The Board Of Trustees Of The Leland Stanford Junior University Coupling of excitation and neurogenesis in neural stem/progenitor cells
TW200616608A (en) 2004-07-09 2006-06-01 Forest Laboratories Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
ES2596809T3 (es) 2004-10-08 2017-01-12 Noven Pharmaceuticals, Inc. Dispositivo de administración transdérmica de fármacos que incluye un refuerzo oclusivo
ATE413166T1 (de) 2004-11-22 2008-11-15 Hisamitsu Pharmaceutical Co Transdermales pflaster enthaltend einen schmelzpunktsenkenden hilfsstoff
US8058291B2 (en) 2005-04-06 2011-11-15 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of CNS-related conditions
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
US20060205822A1 (en) 2004-12-22 2006-09-14 Forest Laboratories, Inc. 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
MX2007007302A (es) 2005-01-11 2008-02-11 Teva Pharm Fine Chemicals Srl Proceso para la preparacion de clorhidrato de 1-amino-3,5-dimetiladamantano.
US20080138388A1 (en) * 2005-02-04 2008-06-12 Hisamitsu Pharmaceutical Co., Inc. Transdermal Absorption Patch
US7888422B2 (en) 2005-11-09 2011-02-15 Mylan Technologies Inc. Long-wearing removable pressure sensitive adhesive
DK2001671T3 (da) * 2006-03-28 2010-08-09 Amcor Flexibles Transpac B V B Halogenfri flerlagsfilm, som er impermeabel for aromaforbindelser
CN1895242B (zh) * 2006-04-13 2011-08-31 沈阳药科大学 双氯芬酸盐的透皮贴剂及制备方法
IL175338A0 (en) 2006-05-01 2006-09-05 Biota Ltd Orally administrable films and preparation thereof
CN101460156B (zh) 2006-05-08 2011-06-08 帝国制药株式会社 抗痴呆药的经皮吸收制剂
US9248104B2 (en) * 2006-08-17 2016-02-02 Core Tech Solutions, Inc. Transdermal methods and systems for treating Alzheimer's disease
US20080107719A1 (en) 2006-11-08 2008-05-08 Sukhon Likitlersuang Transdermal drug delivery system
JP5237112B2 (ja) * 2006-12-01 2013-07-17 日東電工株式会社 経皮吸収製剤
EP2638906A1 (en) 2006-12-01 2013-09-18 Nitto Denko Corporation Stabilized adhesive preparation containing donepezil
JP5403948B2 (ja) 2007-06-07 2014-01-29 久光製薬株式会社 メマンチン含有経皮吸収製剤
AU2008275101B2 (en) 2007-07-10 2014-08-21 Agile Therapeutics, Inc. Dermal delivery device with in situ seal
JP2009203213A (ja) * 2008-02-28 2009-09-10 Kosumedei Seiyaku Kk 経皮吸収医薬組成物
DE102008013701A1 (de) * 2008-03-11 2009-09-17 Lts Lohmann Therapie-Systeme Ag Transdermales Therapeutisches System mit stabilisierter Membran
KR101454362B1 (ko) 2008-03-24 2014-10-23 아이큐어 주식회사 도네페질을 유효성분으로 함유하는 치매 치료용경피흡수제제
US20090291127A1 (en) 2008-05-21 2009-11-26 Jianye Wen Transdermal anti-dementia active agent formulations and methods for using the same
AR074062A1 (es) 2008-10-31 2010-12-22 Lexicon Pharmaceuticals Inc Agonistas del receptor s1p para el tratamiento de la malaria cerebral y forma farmaceutica
US20100178037A1 (en) 2009-01-12 2010-07-15 Te-Wei Chen Display apparatus, video generation apparatus, and method thereof
WO2010083035A2 (en) * 2009-01-14 2010-07-22 Corium International, Inc. Transdermal administration of tamsulosin
JP5758290B2 (ja) 2009-05-01 2015-08-05 久光製薬株式会社 経皮吸収型製剤
CN102630160B (zh) 2009-09-16 2014-05-07 株式会社三养生物制药 透皮递送系统、其制备方法以及使用所述系统的透皮递送方法
AU2010309030B2 (en) 2009-10-21 2013-10-31 Teikoku Seiyaku Co., Ltd. Transdermally absorbable donepezil-containing preparation
CN102048678A (zh) * 2009-10-30 2011-05-11 北京隆旗生物科技有限公司 一种奥昔布宁的透皮吸收制剂及其制备方法与药物应用
GB0921481D0 (en) 2009-12-08 2010-01-20 Vectura Ltd Process and product
JP2012236773A (ja) * 2009-12-16 2012-12-06 Goto Takeshi 抗認知症薬物の経皮吸収製剤
CA2785639A1 (en) 2009-12-30 2011-07-07 Novartis Ag Melt extruded nicotine thin strips
US20100178307A1 (en) * 2010-01-13 2010-07-15 Jianye Wen Transdermal anti-dementia active agent formulations and methods for using the same
US20110244023A1 (en) * 2010-03-30 2011-10-06 Phosphagenics Limited Transdermal delivery patch
ES2547888T3 (es) 2010-04-28 2015-10-09 Hisamitsu Pharmaceutical Co., Inc. Preparación que contiene donepezilo absorbible por vía transdérmica
US9012511B2 (en) 2010-05-19 2015-04-21 Alkermes Pharma Ireland Limited Nanoparticulate cinacalcet compositions
US20140370076A1 (en) 2010-06-30 2014-12-18 Nal Pharmaceuticals, Ltd. Transdermal drug delivery system containing donepezil
NZ605352A (en) * 2010-06-30 2013-10-25 Nal Pharmaceuticals Ltd Process for producing glycosaminoglycans
PT2598119T (pt) 2010-07-29 2018-12-17 Allergan Inc Soluções de brimonidina e timolol isentas de conservantes
MX2013004123A (es) 2010-10-12 2013-12-16 Univ Johns Hopkins Composiciones antitusigenas que comprenden memantina.
JP5699554B2 (ja) 2010-11-11 2015-04-15 富士通株式会社 ベクトル処理回路、命令発行制御方法、及びプロセッサシステム
CA2815898C (en) 2010-11-17 2018-12-18 Hexal Ag Transdermal therapeutic system comprising buprenorphine
WO2012084969A1 (en) 2010-12-22 2012-06-28 Hexal Ag Adhesive composition containing rotigotine and transdermal therapeutic system comprising the adhesive composition
WO2012089256A1 (en) * 2010-12-29 2012-07-05 Pharmafilm S.R.L. Medicated patch for improved transdermal permeation of diclofenac diethylammonium
TWI433904B (zh) 2011-01-12 2014-04-11 Taiwan Biotech Co Ltd 多奈哌齊經皮貼片
US8673338B2 (en) 2011-07-29 2014-03-18 Massachusetts Eye And Ear Infirmary Methods of delivering pharmaceutical agents
KR101239150B1 (ko) 2012-02-28 2013-03-06 에스케이케미칼주식회사 도네페질-함유 경피흡수제제 및 그의 제조방법
US9408802B1 (en) * 2012-03-22 2016-08-09 Prosolus, Inc. Seven day drug in adhesive transdermal delivery
US9145907B2 (en) 2012-08-28 2015-09-29 Hsiutao Liang Pipe connector
US20140256690A1 (en) 2013-03-08 2014-09-11 Agile Therapeutics, Inc. Contraceptive method
WO2014174564A1 (ja) 2013-04-22 2014-10-30 祐徳薬品工業株式会社 メマンチン含有経皮吸収型貼付製剤
JP5415645B1 (ja) 2013-06-28 2014-02-12 久光製薬株式会社 貼付剤の製造方法、貼付剤及び包装体
EP3038608B1 (en) * 2013-08-30 2018-01-03 3M Innovative Properties Company Estradiol containing transdermal drug delivery systems and compositions
RU2646512C2 (ru) 2013-10-07 2018-03-05 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. Устройства для трансдермальной доставки дексмедетомидина и способы их применения
EP3054933A4 (en) * 2013-10-11 2017-03-15 Teikoku Pharma USA, Inc. Topical sphingosine-1-phosphate receptor agonist formulations and methods of using the same
KR101485822B1 (ko) 2014-01-22 2015-01-23 주식회사 대웅제약 도네페질 또는 그의 염을 함유하는 경피흡수제제
JP2015151370A (ja) * 2014-02-14 2015-08-24 日東電工株式会社 貼付製剤
WO2015200472A1 (en) 2014-06-24 2015-12-30 KAT Transdermals LLC Transdermal delivery system
US10071090B2 (en) * 2014-07-18 2018-09-11 Buzzz Pharmaceuticals Limited Oxymorphone transdermal patch
CN106687138B (zh) 2014-09-03 2021-10-15 日东电工株式会社 包含双膦酸盐剂的细胞性免疫用疫苗药物组合物
WO2016046675A1 (en) 2014-09-28 2016-03-31 Mohan M Alapati Compositions and methods for the treatment of neurological diseases
PT3235494T (pt) 2014-12-18 2020-03-05 Icure Pharm Inc Preparação transdérmica contendo donepezilo como ingrediente ativo
EP3250219A4 (en) 2015-01-28 2018-10-03 DNX Biotech, LLC Compositions and methods of using a soluble tnf-alpha receptor modified for increased half-life
CN108135860A (zh) 2015-06-22 2018-06-08 考里安国际公司 包含难溶性治疗剂的透皮粘合剂组合物
CN112843023A (zh) 2015-07-27 2021-05-28 久光制药株式会社 含有阿塞那平的贴剂的制造方法
US10835499B2 (en) 2015-12-30 2020-11-17 Corium, Inc. Systems and methods for long term transdermal administration
CN105693556A (zh) 2016-03-01 2016-06-22 巴斯特医药科技（常州）有限公司 卡巴拉汀酒石酸盐的转化方法及其产物制成的贴片
CN109922796B (zh) 2016-06-23 2023-04-07 考里安有限责任公司 具有亲水和疏水域的粘合剂基质和治疗剂
JP7071330B2 (ja) 2016-07-27 2022-05-18 コリウム， インコーポレイテッド 炭酸水素ナトリウムのｉｎ ｓｉｔｕ変換で促進されたアミン薬物の経皮送達
KR102424270B1 (ko) 2016-07-27 2022-07-25 코리움, 인크. 경구 전달과 생물학적으로 동등한 약물동역학을 가진 경피 전달 시스템
EP3490544A1 (en) 2016-07-27 2019-06-05 Corium International, Inc. Memantine transdermal delivery systems
EP3658127A1 (en) 2017-07-26 2020-06-03 Corium, Inc. Transdermal delivery system with a microporous membrane having solvent-filled pores

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995028914A1 (en) 1994-04-21 1995-11-02 Hisamitsu Pharmaceutical Co., Inc. Percutaneously administrable base composition and percutaneously administrable drug composition prepared therefrom
JP2002275066A (ja) 2001-03-15 2002-09-25 Kyukyu Yakuhin Kogyo Kk 粘膜貼付剤
US20040022835A1 (en) 2002-01-17 2004-02-05 Samyang Corporation Transdermal composition of an antivomiting agent
WO2005115355A1 (ja) 2004-05-28 2005-12-08 Hisamitsu Pharmaceutical Co., Inc. 貼付製剤
JP2008530217A (ja) 2005-02-18 2008-08-07 マイラン・テクノロジーズ，インコーポレイテッド 制御送達システムを有する経皮システム
JP2007302582A (ja) 2006-05-09 2007-11-22 Hisamitsu Pharmaceut Co Inc ドネペジル経皮吸収型製剤
JP2009542657A (ja) 2006-06-29 2009-12-03 ジャズ ファーマシューティカルズ ゲルの形態でのロピニロール含有薬学的組成物、その使用
JP2012255044A (ja) 2006-12-01 2012-12-27 Nitto Denko Corp ドネペジル含有貼付製剤の経時的な変色を抑制する方法
JP2010538064A (ja) 2007-09-04 2010-12-09 マイラン・テクノロジーズ，インコーポレイテッド 被覆剥離ライナを含む経皮薬物送達システム
JP2011518795A (ja) 2008-04-25 2011-06-30 アシノ アーゲー フェンタニルまたはその類似化合物を投与するための経皮治療システム
WO2011105486A1 (ja) 2010-02-24 2011-09-01 久光製薬株式会社 貼付剤
JP2013528631A (ja) 2010-06-17 2013-07-11 エルテーエス ローマン テラピー−ジステーメ アーゲー メマンチンの経皮投与
JP2014514351A (ja) 2011-05-12 2014-06-19 シャンハイ テックウェル バイオファーマスーティカル カンパニー リミテッド ミカファンギンナトリウムの製造方法
JP2013075856A (ja) 2011-09-30 2013-04-25 Tokuyama Corp 貼付剤
WO2015072564A1 (ja) 2013-11-17 2015-05-21 株式会社メドレックス 経皮吸収型コロイド液剤

Also Published As

Publication number Publication date
JP2019523268A (ja) 2019-08-22
US20220016045A1 (en) 2022-01-20
MX2019001103A (es) 2019-09-27
AU2025205205A1 (en) 2025-07-24
AU2017301928B2 (en) 2023-04-06
CN109789105B (zh) 2022-12-27
KR102555208B1 (ko) 2023-07-17
RU2019105279A3 (enExample) 2020-12-23
CA3281579A1 (en) 2025-10-31
KR102406536B1 (ko) 2022-06-08
CN116966166A (zh) 2023-10-31
KR20190034601A (ko) 2019-04-02
MX2022006681A (es) 2022-07-11
US20180028462A1 (en) 2018-02-01
JP2022093707A (ja) 2022-06-23
KR102406482B1 (ko) 2022-06-08
MX394249B (es) 2025-03-24
JP2019525932A (ja) 2019-09-12
KR102406528B1 (ko) 2022-06-08
US20180028663A1 (en) 2018-02-01
JP2022121629A (ja) 2022-08-19
KR20190032512A (ko) 2019-03-27
US11103463B2 (en) 2021-08-31
AU2023203616A1 (en) 2023-07-06
AU2023204240A1 (en) 2023-07-27
KR102545643B1 (ko) 2023-06-21
US9993466B2 (en) 2018-06-12
WO2018022815A3 (en) 2018-03-08
WO2018022816A1 (en) 2018-02-01
US20250325496A1 (en) 2025-10-23
CN109789105A (zh) 2019-05-21
US20180028512A1 (en) 2018-02-01
KR20220082098A (ko) 2022-06-16
US20250375395A1 (en) 2025-12-11
EP3490540A1 (en) 2019-06-05
AU2023203618A1 (en) 2023-07-06
US20180028463A1 (en) 2018-02-01
AU2017302307A1 (en) 2019-02-14
CA3031945A1 (en) 2018-02-01
US20210015761A1 (en) 2021-01-21
JP2019523270A (ja) 2019-08-22
WO2018022817A1 (en) 2018-02-01
AU2023203618B2 (en) 2025-09-18
KR20220082928A (ko) 2022-06-17
CA3032148A1 (en) 2018-02-01
RU2019105279A (ru) 2020-08-27
US10300025B2 (en) 2019-05-28
EP3490558A1 (en) 2019-06-05
CN109789133A (zh) 2019-05-21
US20180235901A1 (en) 2018-08-23
US20250375396A1 (en) 2025-12-11
US20190247320A1 (en) 2019-08-15
JP7153010B2 (ja) 2022-10-13
KR20190035801A (ko) 2019-04-03
CN109789106B (zh) 2023-06-27
US20240156747A1 (en) 2024-05-16
AU2017302306A1 (en) 2019-02-14
CA3032044C (en) 2024-10-01
WO2018022815A2 (en) 2018-02-01
CA3031945C (en) 2025-09-23
EP3490541A2 (en) 2019-06-05
EP3490541B1 (en) 2025-07-09
JP2022140751A (ja) 2022-09-27
CN116270551A (zh) 2023-06-23
KR20220082929A (ko) 2022-06-17
CN109789106A (zh) 2019-05-21
JP7251033B2 (ja) 2023-04-04
KR20230109782A (ko) 2023-07-20
AU2017301928A1 (en) 2019-02-14
CA3032044A1 (en) 2018-02-01
US10307379B2 (en) 2019-06-04
KR20230098349A (ko) 2023-07-03
US20190247321A1 (en) 2019-08-15
KR20230097203A (ko) 2023-06-30
KR102545649B1 (ko) 2023-06-22
SG11201900692WA (en) 2019-02-27

Similar Documents

Publication Publication Date Title
US20250375396A1 (en) Sodium bicarbonate in situ conversion driven transdermal delivery of amine drug
JP2003528037A (ja) 気管支拡張剤ツロブテロールを皮膚から投与するための塩酸ツロブテロールを含む経皮治療システム
JP3066515B2 (ja) 尿失禁治療用経皮投与製剤
JPH04217919A (ja) エペリゾンまたはトルペリゾン経皮吸収製剤
JPH07103016B2 (ja) 貼付剤およびその製造方法
CA3032148C (en) Sodium bicarbonate in situ conversion driven transdermal delivery of amine drug
KR20190039692A (ko) 메틸페니데이트 또는 이의 염을 함유하는 경피 전달 시스템 및 이의 방법
US8124122B2 (en) Female hormone-containing patch

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200720

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200720

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210709

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211005

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211209

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220408

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220506

R150 Certificate of patent or registration of utility model

Ref document number: 7071330

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250